天士力 (600535.SH) Latest Company News

Aug 31, 2026, 21:41 UTC
Tasly's net profit attributable to shareholders increased by 15.23% in the first half of 2026 despite a slight revenue decline, with 10 products newly included in the 2026 National Essential Medicines List.
Source:
- wap.eastmoney.com
Aug 21, 2026, 15:58 UTC
Tasly Pharmaceutical Group announced that 10 of its products, including two exclusive products Jinghua Weikang Jiaowan and Shaoma Zhijing Granules, were newly included in the 2026 National Essential Medicines List.
Source:
- wap.eastmoney.com
Aug 21, 2026, 10:33 UTC
Tasly Pharmaceutical Group announced a cash dividend of 2.4 yuan per 10 shares (tax inclusive), totaling 359 million yuan (tax inclusive).
Source:
- finance.sina.cn
Aug 21, 2026, 10:30 UTC
Tasly Pharmaceutical Group reported first-half revenue of 4.20 billion RMB and net profit of 892.7 million RMB.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 10, 2026, 09:26 UTC
Tasly announced executive changes: Xi Kai to become general manager and be added as non-independent director, Cai Jinyong to become chairman, and Zhong Jiang to step down as non-independent director.
Source:
- finance.sina.cn
Jul 17, 2026, 09:34 UTC
Tianjin Tasly Pharmaceutical's subsidiary Tasly Biologics received regulatory approval from the National Medical Products Administration to conduct clinical trials for its drug Puyouke (recombinant human prourokinase for injection) in an expanded time window for acute ischemic stroke patients.
Source:
- finance.sina.cn
Jul 14, 2026, 09:29 UTC
Tianjin Tasly Pharmaceutical Co., Ltd. announced its 2026 semi-annual financial results, reporting net profit of 893 million yuan, up 15.23% year-on-year.
Source:
- finance.sina.cn
- rttnews.com

600535.SH

Tasly's net profit attributable to shareholders increased by 15.23% in the first half of 2026 despite a slight revenue decline, with 10 products newly included in the 2026 National Essential Medicines List.

Tasly Pharmaceutical Group announced that 10 of its products, including two exclusive products Jinghua Weikang Jiaowan and Shaoma Zhijing Granules, were newly included in the 2026 National Essential Medicines List.

Tasly Pharmaceutical Group announced a cash dividend of 2.4 yuan per 10 shares (tax inclusive), totaling 359 million yuan (tax inclusive).

Tasly Pharmaceutical Group reported first-half revenue of 4.20 billion RMB and net profit of 892.7 million RMB.

Tasly announced executive changes: Xi Kai to become general manager and be added as non-independent director, Cai Jinyong to become chairman, and Zhong Jiang to step down as non-independent director.

Tianjin Tasly Pharmaceutical's subsidiary Tasly Biologics received regulatory approval from the National Medical Products Administration to conduct clinical trials for its drug Puyouke (recombinant human prourokinase for injection) in an expanded time window for acute ischemic stroke patients.

Tianjin Tasly Pharmaceutical Co., Ltd. announced its 2026 semi-annual financial results, reporting net profit of 893 million yuan, up 15.23% year-on-year.